

# INVESTOR'S PRESENTATION



# EIKO LIFESCIENCES

F E E L T H E C H E M I S T R Y

## **Eiko LifeSciences Limited**

(Formerly known as Narendra Investments (Delhi) Ltd.)

Regd. Office Address: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane MH 400604 Phone No.: 022-2539 0009;

Email id: [investor.relations@eikolifesciences.com](mailto:investor.relations@eikolifesciences.com) BSE Code: Eiko | 540204 |



## **SAFE HARBOR**

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Eiko LifeSciences Limited** (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever.

Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



# **The Ethos- Vision and Mission**



## **ABOUT THE COMPANY**

**Eiko LifeSciences Ltd.**, was originally Incorporated in 1977 (BSE Code: EIKO| 540204 |) has recently ventured in the business of Manufacturing, Supplying and Export of Speciality & Fine Chemicals. Company has successfully ventured in the business by amending the main object of the company. In a short span of just three quarters of operations, Eiko has launched several new products and established itself as a leading player in the field of Speciality and fine Chemicals.

## **VISION**

To become one of the prominent Speciality & Fine chemical company with distinctive integrated production models and varied products portfolio on a global arena.

## **MISSION**

To achieve sustainable growth in business by providing best quality products & services to customers, taking utmost care of all our stakeholders and focus on Environment, Social and Governance policies.



# Company Overview



**In a short span of time, company has established itself in the race of becoming India's leading Speciality & Fine Chemicals Manufacturer, Supplier & Exporting company.**

- Company's Speciality Chemicals product offerings comprise of Organic as well as and Inorganic chemicals.
- Its products are used in Pharmaceuticals, Agrochemicals, Aroma Chemicals, Electronic Chemicals etc.
- Company has expanded its range of products and, presently, manufactures leading Speciality Chemicals which find application across various industries in India and globally.
- To begin with, Company operates out of its leased unit at MIDC, Badlapur and has also tied up with many job workers.



# **Q-1/ FY 21-22 Financial Performance**

## Financial Highlights (₹ in Lakhs)

Particulars	Q1 FY2021-22	Q4 FY2020-21	% Change
Total Income	 857.19	628.15	 36%
EBIDTA	 67.45	55.64	 21%
PBT	 53.62	48.55	 10%
PAT	 40.12	35.48	 13%

## Other Highlights of the Quarter

- During the quarter ended 30<sup>th</sup> June 2021, paid up Share capital of the company increased from Rs. 3.82 Cr to Rs. 8.32 Cr on account of issuance and allotment of 24,29,967 New Equity Shares having a face value of Rs. 10/- each, issued for cash at Rs. 30/- per share aggregating to Rs. 7,28,99,010/- and 20,66,300 New equity shares having a face value of Rs. 10/- each, issued for consideration other than cash at Rs. 70/- per share aggregating to Rs. 14,46,41,000/- on a preferential basis.
- By end of this quarter, Company has availed the working capital facilities from ICICI Bank at best possible terms. This will also help the company to meet the increasing demand of its products.
- Pursuant to change in the main object and operations of the company, name of the company was changed from Narendra Investments (Delhi) Ltd to **Eiko LifeSciences Ltd.**
- Company is listed on BSE Ltd., and pursuant to change of name of the company, BSE Code stands changed from NIDL to **“EIKO”**



# **Our Products & Business**

# OUR Business Profile

Our Business is broadly categorized

Intermediates for Pharmaceuticals, Fine Chemicals & Agrochemicals

Company is also proposing to venture into APIs business, as a part of forward integration strategy



# OUR Products Profile

## 3-Chloropropiophenone, Orthochlorobenzonitrile (2-Chlorobenzonitrile)



Halogenated products such as Bromo/ Chloro derivatives of various Aromatics Compounds



key precursors for variety of life saving drugs such as Amiodarone (Cardiovascular), Bupropion (Anti Smoking) etc.

## Fine Chemicals



used for perfumery, food & flavor Industry such as Coumarin and its derivatives



**Various other products used for applications like electro plating/ e-coating, metal finishing etc.**

## Agrochemicals intermediates



Used in manufacturing of Speciality Fungicides and Herbicides such as Chlorinated derivatives of Quinoline



widely used for broad Spectrum Herbicides applications



## **End users of our Products**

**PHARMA  
CEUTICALS**



**NUTRA  
CEUTICALS**



**AGRO  
CHEMICALS**



**CONSTRUCTION  
CHEMICALS**



**DYES & PIGMENTS**



**FLAVORS &  
FRAGRANCES**





# Competitive Advantages



## **Eiko LifeSciences Ltd. has the following Competitive Advantages:**

---

Large and diverse array of products

---

Strong relations with Manufacturing facilities

---

Diversified and Stable Customer Base

---

Strong Relations with Marquee Clients

---

Experienced team with domain knowledge

---

Established and stable relationship with suppliers

---

Specialised Business Model with high entry barriers

---

Continuous R & D

---

Improved Profit Margins

---



## **Experienced Promoters, Board of Directors and KMPs**



**Operations** of the Company are being professionally managed by a team of experienced technocrats under guidance from Board of Directors

- CA Laxmikant Kabra (Chairman, Promoter Director)
- Mr. Bhavesh Dhirajlal Tanna (Promoter Director)
- Mr. Umesh More (Executive Director)
- Ms. Kajal Kothari (Independent Director)
- CA Mandar Kamalakar Patil (Independent Director)
- Mr. Rajkumar Baheti (Independent Director)



**Thanks!**

**Any questions?**

You can find us at:  
[business@eikolifesciences.com](mailto:business@eikolifesciences.com)